AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Statkraft, Europe's largest renewable energy producer, and the biopharmaceutical company AstraZeneca have entered into an agreement on wind power deliveries that will increase the supply of renewable electricity in Sweden. The agreement is based on the commissioning of new wind farms. Under the agreement, AstraZeneca commits to purchasing 200 gigawatt-hours per year for ten years, equivalent to two terawatt-hours. This corresponds to approximately 80 percent of the company's total electricity needs at its research facility in Gothenburg and manufacturing facility in Södertälje. AstraZeneca in Sweden has been using 100 percent certified renewable energy for several years. Through the agreement with Statkraft, the company will also be able to increase access to renewable energy in the community where it operates. The three wind farms are in Strömstad and Årjäng, which is in Sweden's bidding area 3 (SE3), where AstraZeneca's research and manufacturing facilities are also situated. The wind farms are owned by Rabbalshede Kraft, who will also be responsible for their operation. In its Swedish operations, AstraZeneca is also working to reduce its electricity consumption, for example, through the recycling of excess heat and optimization of humidity and temperature in its facilities. “We want to contribute to the green transition in society. It is important for us to support initiatives that increase the availability of renewable energy. To successfully mitigate climate change, we must collaborate across different sectors and think beyond our own operations. Here we see an opportunity to contribute to the increase of renewable energy in society,” says Per Alfredsson, President AstraZeneca AB, Sweden. Globally, AstraZeneca aims to halve its entire value chain footprint (Scope 3) by 2030, on the way to a 90 percent reduction by 2045 from a 2019 baseline. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Net Zero Corporate Standard. “We are very pleased to support this ambitious initiative for a sustainable transition. This agreement confirms the role of Statkraft as a leading supplier of renewable energy to Nordic industries and our ambition to be a leading market integrator in the energy system”, says Hallvard Granheim, Executive Vice President Markets at Statkraft.

Statkraft and AstraZeneca sign agreement on wind power delivery

CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.

China's CanSino in mRNA vaccine deal with AstraZeneca

AstraZeneca's phenomenal medicine portfolio pushed up revenue and profits in the second quarter. The company is committed to innovation.

Is This Blue Chip Dividend Stock a Buy for Growth Investors?

AstraZeneca second indicated to 2023 with eight different medicines delivering over US$1 billion in sales in the first half, notes Shore Capital. AZN also had eight separate Phase III oncology trials read out positively with a swathe of additional data still to come over the remainder of the year.

AstraZeneca is a premium growth story says broker

Sanofi

Infants should get a new drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, heath advisers recommended Thursday.

CDC panel says babies should get new drug that prevents RSV

The U.S. Centers for Disease Control and Prevention said on Thursday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.

US CDC approves Sanofi-AstraZeneca's preventive RSV therapy for babies

Merck

Pfizer

Identifying promising pharma stocks is no small feat in the dynamic and competitive realm of pharmaceuticals. The industry is replete with businesses boasting robust pipelines, each vying for a breakthrough that could potentially revolutionize healthcare.

3 Pharma Stocks to Buy for Their Promising Progress

AstraZeneca's revenue for the second quarter of 2023 was $11.42 billion, up 5% from the previous quarter and 6% from the second quarter of 2022. At the end of June 2023, AstraZeneca's total debt was about $30.8 billion, down $1.68 billion from the previous quarter. Calquence's revenue was $653 million in Q2 2023, up 33.55% year-on-year.

AstraZeneca's Q2 Earnings Exceed Expectations, Astonishing Investors (Rating Upgrade)

AstraZeneca plc (LON: AZN) was in focus on Friday after the pharma giant announced a deal worth up to $1.0 billion with its U.S. peer Pfizer Inc (NYSE: PFE). Details of the AstraZeneca-Pfizer deal The London-listed firm is buying a group of preclinical gene therapies from Pfizer to expand its footprint in rare diseases.

AstraZeneca reveals a $1.0 billion deal with Pfizer

AstraZeneca PLC (NASDAQ:AZN ) Q2 2023 Earnings Conference Call July 28, 2023 6:45 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredrickson - Executive Vice-President, Oncology Business Unit Susan Galbraith - Executive Vice President, Oncology Research & Development Ruud Dobber - EVP of BioPharmaceuticals Business Unit Mene Pangalos - Executive Vice-President, BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer, Alexion Leon Wang - Executive Vice-President, International & China President Conference Call Participants Sachin Jain - Bank of America Tim Anderson - Bernstein Andrew Baum - Citi Mark Purcell - Morgan Stanley Gonzalo Artiach - ABG Richard Parkes - Exane Christopher Uhde - SEB James Gordon - JPMorgan Emily Field - Barclays Victor Sanders - Nordea Steve Scala - Cowen Simon Baker - Redburn Seamus Fernandez - Guggenheim Matt Weston - Credit Suisse Eric Le Berrigaud - Stifel Peter Welford - Jefferies Luisa Hector - Berenberg Operator Good morning to those joining from the UK and the US. Good afternoon to those in Central Europe, and good evening to those listening in Asia.

AstraZeneca PLC (AZN) Q2 2023 Earnings Call Transcript

AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications.

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales

AstraZeneca's shares rose on Friday after it announced the purchase of Pfizer's rare disease portfolio for up to $1 billion and reported better-than-expected financial results on strong sales of its cancer drugs.

AstraZeneca Shares Surge After Revenue Beat on Cancer Drug Sales, $1 Billion Pfizer Deal

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Astrazeneca (AZN) Q2 Earnings: A Look at Key Metrics

AstraZeneca PLC's (LSE:AZN) underlying quarterly performance shows it is "far from a one-trick pony" and its share price premium over peers is entirely warranted, broker Shore Capital said. Alongside the announcement of a US$1bn acquisition, second-quarter results from the biggest company on the FTSE 100 showed a stronger top line of U$11.4bn than consensus forecasts, up 6% as the unwinding of Covid-19 medicines created a drag.

AstraZeneca number show how it is 'not a one-trick pony' - analyst

BeiGene

Exelixis

Kura Oncology

Novartis

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

7 Best Cancer Stocks to Invest in Now

Aradhana Sarin told CNBC the company was in a "very unique space" regarding impact from rising geopolitical tensions between China and the west.

AstraZeneca CFO denies geopolitics impacts the company's China business after spinoff rumors

AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful".

AstraZeneca CEO says lung cancer drug trial data 'very encouraging'

AstraZeneca PLC's rare disease unit, Alexion, has unveiled a $1 billion agreement to acquire Pfizer's early-stage gene therapy portfolio, a strategic move designed to bolster its footprint in the burgeoning field of genomic medicine. The deal, which is expected to be concluded in the third quarter, will bring Alexion a number of preclinical programmes and technologies, alongside a set of adeno-associated virus (AAV) capsids vital for gene therapy and editing.

AstraZeneca unit strikes $1bn rare diseases deal with Pfizer

AstraZeneca said on Friday its unit Alexion has agreed to buy a portfolio of U.S. drugmaker Pfizer's early-stage rare disease gene therapy for up to $1 billion, plus royalties on sales.

AstraZeneca signs $1 bln deal with Pfizer for gene therapy portfolio

AstraZeneca on Friday beat expectations for its second-quarter profit, helped by better-than-expected sales of its oncology drugs.

AstraZeneca second quarter profit beats expectations

NatWest Group plc 

A month ago NatWest Group PLC (LSE:NWG) would have expected a fairly calm set of interim results focusing on its UK and investment banking divisions. That was before Nigel Farage's Coutts account was closed, sparking a battle with the bank that ended with the toppling of boss Alison Rose.

NatWest adjusts to life after Rose, plus AstraZeneca and BA interims due on Friday

AstraZeneca (AZN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why AstraZeneca (AZN) Might Surprise This Earnings Season

AstraZeneca (LON: AZN) share price has struggled in the past few weeks as concerns about its cancer drug. After soaring to a record high of 12,350 in April, the stock has plunged by ~14% to 10,650, meaning it has moved into a correction.

AstraZeneca share price: death cross nears ahead of earnings

Certain industries have reduced their presence and or reliance on the Chinese market in 2023, but Big Pharma isn't one of them, according to reporting from the Wall Street Journal.  The company's aging population, an increasing share of the which is living with a chronic lifestyle disease, makes for an attractive market.

Big Pharma bets on China's aging population

Ameren

Biogen

CME Group

CNH Industrial NV

Genuine Parts

Intercontinental Exchange

iShares Trust iShares 1-5 Year Investment Grade Corporate Bond ETF

Itau Unibanco Holding S.A.

Cie Generale des Etablissements Michelin SCA

Mueller Industries

Paramount Global

Siemens AG

Sylvamo Corp

TEGNA

Target

Textron

Barron's Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies, of-which YCharts reported 25 as paying dividends. Barron's interviews with their ten financial-industry Roundtable pros tapped human intelligence (HI) to make predictions. Unfortunately, the YCharts screener employed to report current data, dropped seven funds off the list. Nevertheless, the Watchlist tracked by YCharts as of 7/19/23 projected ten top analyst-estimated net gains from ICE, PARA, TXT, AZN, MLI, BIIB, SIEGY, CHNI, TGNA, & topped by SLVM, ranging from 15.53%-31.31%.

4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys

News for AstraZeneca Stock (AZN)